Overview

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Axitinib